Dermatomyositis Flare With Immune Checkpoint Inhibitor Therapy for Melanoma

Immune checkpoint inhibitor (ICI) medications have seen expanded use in the management of numerous malignancies. These therapies encompass a unique spectrum of immune-related adverse events (irAEs). Rheumatological irAEs from ICIs have been described in various case reports; however, limited literat...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Rachel, Patel, Hamish, Scott, Joshua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/
https://www.ncbi.nlm.nih.gov/pubmed/33981507
http://dx.doi.org/10.7759/cureus.14387

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8106943/
https://www.ncbi.nlm.nih.gov/pubmed/33981507
http://dx.doi.org/10.7759/cureus.14387

Ejemplares similares